ArticleSurgical endoscopy2026
Surgical approach and tumor size influence outcomes in thymoma: a retrospective analysis of 70 cases.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMinimally invasive surgery (MIS) has become increasingly applied in thymoma, but its feasibility for large tumors remains contested.
methodsWe retrospectively reviewed 70 patients, treated between 2001 and 2023, with Masaoka stage I-II thymomas. Patients were stratified according to surgical approach-open surgery (OP, n = 20) or MIS (video- or robot-assisted, n = 50)-and tumor size using both preoperative CT and specimen measurements with 5- and 6 cm thresholds. Perioperative outcomes were compared using propensity score matching (PSM).
resultsMIS was associated with less intraoperative blood loss, shorter drainage duration, and shorter hospital stay compared with OP, without conversions to OP. These benefits persisted after PSM. The use of MIS gradually expanded to include tumors ≥ 5 cm, with perioperative outcomes improving in a later phase. Within the MIS cohort, tumor size ≥ 5 cm did not significantly affect operative time, blood loss, or recovery. Exploratory analyses using a 6 cm cutoff showed comparable overall outcomes. Oncologic events were rare, with only one recurrence observed in the entire cohort.
conclusionsMIS offers superior short-term perioperative outcomes compared with OP and appears feasible for selected patients with large thymomas. However, its long-term oncologic validity-particularly regarding pleural dissemination and late recurrence-requires confirmation in multicenter prospective studies.
Indexed as
Identifiers
41366574What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.